Search
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnDaclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydroch...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesViloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnViloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-releas...
Categories: Adrenergic alpha-1 Receptor Antagonists, Cytochrome P-450 SubstratesUbidecarenone
go.drugbank.com/drugs/DB09270ApprovedInvestigationalNutraceuticalUbidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid...
Categories: P-glycoprotein substratesTenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigationalTenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on te...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesLevobetaxolol
go.drugbank.com/drugs/DB09351ApprovedLevobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesEsterified estrogens
go.drugbank.com/drugs/DB09381ApprovedEsterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterifi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigationalIxazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center, it is considered a boronate proteasome inhibitor. More than 99% of the drug compound is the R-enantiomer. Ixazomib was a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesButamben
go.drugbank.com/drugs/DB11148ApprovedWithdrawnButamben is a local anesthetic in the form of n-butyl-p-aminobenzoate.
Dihydroergocornine
go.drugbank.com/drugs/DB11273ApprovedDihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects. It is an artificial derivative of the crude extract of ergot and later purified, ergocornine. The formation of dihydroergocornin...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates